FrancophonIA/ELRC3.0 huggingface dataset:
English: The active substance in Bydureon, exenatide, is an ‘incretin mimetic'.
Slovenian: Zdravilna učinkovina v zdravilu Bydureon, eksenatid, je „mimetik inkretina“.
English: Bydureon contains the active substance exenatide.
Slovenian: Zdravilo Bydureon vsebuje zdravilno učinkovino eksenatid.
English: The third study (in 514 patients) compared Bydureon with sitagliptin or pioglitazone as add-on treatment to metformin.
Slovenian: V tretji študiji (pri 514 bolnikih) so zdravilo Bydureon primerjali s sitagliptinom ali pioglitazonom kot dodatnim zdravilom pri zdravljenju z metforminom.
English: In the sixth study (in 464 patients), Bydureon given together with insulin glargine with or without metformin was compared with placebo (dummy treatment) also given with insulin glargine with or without metformin.
Slovenian: V šesti študiji (pri 464 bolnikih) so zdravilo Bydureon v kombinaciji z insulinom glarginom skupaj z metforminom ali brez njega primerjali s placebom (zdravilom brez zdravilne učinkovine), ki so ga prav tako dajali v kombinaciji z insulinom glarginom skupaj z metforminom ali brez njega.
English: How does Bydureon work?
Slovenian: Kako zdravilo Bydureon deluje?
English: How is Bydureon used?
Slovenian: Kako se zdravilo Bydureon uporablja?
English: In the fifth study (in 695 patients), Bydureon given with dapagliflozin was compared with Bydureon alone and dapagliflozin alone.
Slovenian: V peti študiji (pri 695 bolnikih) so zdravljenje s kombinacijo zdravila Bydureon in dapagliflozina primerjali z zdravljenjem samo z zdravilom Bydureon ali dapagliflozinom kot samostojnima zdraviloma.
English: In the first study, Bydureon reduced HbA1c levels by an average of 1.9 percentage points after 30 weeks of treatment, compared with an average reduction of 1.5 points with exenatide given twice daily.
Slovenian: V prvi študiji je zdravilo Bydureon znižalo ravni HbA1c v povprečju za 1,9 odstotne točke po 30 tednih zdravljenja v primerjavi s povprečnim znižanjem za 1,5 odstotne točke pri jemanju eksenatida dvakrat na dan.
English: In the second study, the average reduction was 1.6 points after 24 weeks of treatment with Bydureon, compared with an average reduction of 0.9 points with exenatide given twice daily.
Slovenian: V drugi študiji je bilo povprečno znižanje ravni HbA1c po 24 tednih zdravljenja z zdravilom Bydureon 1,6 točke v primerjavi s povprečnim znižanjem za 0,9 točke pri jemanju eksenatida dvakrat na dan.
English: The average reduction with Bydureon plus dapagliflozin was 2.0 points after 28 weeks, compared with an average reduction of 1.6 points with Bydureon alone and 1.4 points with dapagliflozin alone.
Slovenian: Povprečno znižanje pri zdravljenju s kombinacijo zdravila Bydureon in dapagliflozina je bilo po 28 tednih za 2,0 točke v primerjavi s povprečnim znižanjem za 1,6 točke pri zdravljenju z zdravilom Bydureon oziroma 1,4 točke pri zdravljenju z dapagliflozinom kot samostojnima zdraviloma.
English: Bydureon reduced HbA1c levels by an average of 1.4 points after 26 weeks of treatment, compared with an average reduction of 0.8 and 1.1 points with sitagliptin and pioglitazone respectively.
Slovenian: Zdravilo Bydureon je ravni HbA1c po 26 tednih zdravljenja v povprečju znižalo za 1,4 točke v primerjavi s povprečnim znižanjem za 0,8 točke pri zdravljenju s sitagliptinom in 1,1 točke pri zdravljenju s pioglitazonom.
English: At the start of the study, the patients' HbA1c levels were around 9.3%.
Slovenian: Na začetku študije je bila raven HbA1c pri bolnikih okoli 9,3 %.
English: The fourth study (in 456 patients) compared Bydureon with insulin glargine (a long-acting insulin) as add-on treatment to metformin with or without a sulphonylurea.
Slovenian: V četrti študiji (pri 456 bolnikih) so zdravilo Bydureon kot dodatno zdravilo pri zdravljenju z metforminom s sulfonilsečnino ali brez nje primerjali z insulinom glarginom (dolgodelujočim insulinom).
English: The average reduction with Bydureon was 1.0 point after 28 weeks, compared with an average reduction of 0.2 points with placebo.
Slovenian: Po 28 tednih zdravljenja z zdravilom Bydureon se je raven HbA1c v povprečju znižala za 1,0 točke v primerjavi s povprečnim znižanjem za 0,2 točke pri zdravljenju s placebom.
English: The average reduction with Bydureon was 1.5 points after 26 weeks, compared with an average reduction of 1.3 points with insulin glargine.
Slovenian: Po 26 tednih zdravljenja z zdravilom Bydureon se je raven HbA1c v povprečju znižala za 1,5 točke v primerjavi s povprečnim znižanjem za 1,3 točke pri zdravljenju z insulinom glarginom.
English: At the start of the studies, the patients' HbA1c levels were around 8.4%.
Slovenian: Na začetku študij je bila raven HbA1c pri bolnikih okoli 8,4 %.
English: At the start of the study, the patients' HbA1c levels were around 8.5%.
Slovenian: Na začetku študije je bila raven HbA1c pri bolnikih okoli 8,5 %.
English: At the start of the study, the patients' HbA1c levels were around 8.3%.
Slovenian: Na začetku študije je bila raven HbA1c pri bolnikih okoli 8,3 %.
English: The most important serious side effects are serious infections.
Slovenian: Najpomembnejši resni neželeni učinki so resne okužbe.
English: However, these side effects are considered manageable.
Slovenian: Vendar se ti neželeni učinki štejejo za obvladljive.
English: Further information on Rinvoq can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/rinvoq.
Slovenian: Nadaljnje informacije o zdravilu Rinvoq so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/rinvoq.
English: It is available as 15 mg tablets.
Slovenian: Zdravilo je na voljo v obliki 15-miligramskih tablet.
English: This means that it reduces the activity of the immune system.
Slovenian: To pomeni, da zavira delovanje imunskega sistema.
English: It must also not be used in patients with severe liver problems or during pregnancy.
Slovenian: Prav tako se ne sme uporabljati pri bolnikih z resnimi težavami z jetri ali med nosečnostjo.
English: Studies found that it reduced disease activity when used alone or combined with other medicines.
Slovenian: Študije so pokazale, da zdravilo zmanjša aktivnost bolezni, če se uporablja samostojno ali v kombinaciji z drugimi zdravili.
English: The European Medicines Agency therefore decided that Rinvoq's benefits are greater than its risks and that it can be authorised for use in the EU.
Slovenian: Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Rinvoq večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
English: These studies involved rating disease activity in 28 joints in the body on a standard scale.
Slovenian: V teh študijah se je s standardno lestvico ocenjevalo aktivnost bolezni v 28 sklepih v telesu.
English: The recommended dose of Rinvoq is one tablet once a day.
Slovenian: Priporočeni odmerek zdravila Rinvoq je ena tableta enkrat na dan.
English: What measures are being taken to ensure the safe and effective use of Rinvoq?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Rinvoq?
English: Treatment with the medicine should be started and supervised by a doctor experienced in diagnosing and treating rheumatoid arthritis.
Slovenian: Zdravljenje z zdravilom mora uvesti in nadzorovati zdravnik, ki ima izkušnje z diagnosticiranjem in zdravljenjem revmatoidnega artritisa.
English: The doctor may interrupt treatment in case of certain side effects, including falls in blood cell counts.
Slovenian: Zdravnik lahko zdravljenje prekine v primeru nekaterih neželenih učinkov, vključno z zmanjšanjem števila krvnih celic.
English: Upadacitinib works by blocking the action of enzymes called Janus kinases.
Slovenian: Upadacitinib deluje tako, da zmanjša delovanje encimov, imenovanih Janusove kinaze.
English: The patients were being treated with conventional disease-modifying anti-rheumatic medicines (chloroquine, hydroxychloroquine, leflunomide or sulfasalazine, often combined with methotrexate).
Slovenian: Bolniki so bili zdravljeni z običajnimi imunomodulirajočimi antirevmatiki (klorokvinom, hidroksiklorokvinom, leflunomidom ali sulfasalazinom, pogosto v kombinaciji z metotreksatom).
English: As for all medicines, data on the use of Rinvoq are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Rinvoq stalno spremljajo.
English: For more information about using Rinvoq, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Rinvoq glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: The most common side effects with Rinvoq (which may affect more than 1 in 10 people) are upper respiratory tract infections (nose and throat infections).
Slovenian: Najpogostejši neželeni učinki zdravila Rinvoq (ki se lahko pojavijo pri več kot 1 bolniku od 10) so okužbe zgornjih dihalnih poti (okužbe nosu in žrela).
English: Other information about Rinvoq
Slovenian: Druge informacije o zdravilu Rinvoq
English: Side effects reported with Rinvoq are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Rinvoq, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Rinvoq have also been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Rinvoq upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: An overview of Rinvoq and why it is authorised in the EU
Slovenian: Pregled zdravila Rinvoq in zakaj je odobreno v EU
English: Rinvoq must not be used in patients with tuberculosis or serious infections.
Slovenian: Zdravilo Rinvoq se ne sme uporabljati pri bolnikih s tuberkulozo ali resnimi vnetji.
English: What benefits of Rinvoq have been shown in studies?
Slovenian: Kakšne koristi zdravila Rinvoq so se pokazale v študijah?
English: These enzymes are involved in setting up processes that lead to inflammation, and blocking their effect brings inflammation in the joints under control.
Slovenian: Ti encimi so vključeni v nastajanje procesov, ki povzročajo vnetje, z zaviranjem njihovega učinka pa omogoča nadzor nad vnetjem sklepov.
English: In patients with rheumatoid arthritis, the immune system (the body's defences) attacks healthy tissue, causing inflammation in the joints.
Slovenian: Pri bolnikih z revmatoidnim artritisom imunski sistem (obrambni mehanizem telesa) napade zdravo tkivo in povzroči vnetje v sklepih.
English: Why is Rinvoq authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Rinvoq odobreno v EU?
English: Five studies involving a total of nearly 4,400 patients found Rinvoq effective in reducing symptoms in patients with moderate to severe rheumatoid arthritis.
Slovenian: V petih študijah, v katerih je sodelovalo skupaj skoraj 4 400 bolnikov, je bilo ugotovljeno, da zdravilo Rinvoq učinkovito zmanjšuje simptome pri bolnikih z zmernim do hudim revmatoidnim artritisom.
English: The company that markets Rinvoq will provide information to healthcare professionals about the risks of infection, harm to the unborn baby if Rinvoq is taken during pregnancy, and problems affecting the heart and circulation.
Slovenian: Podjetje, ki trži zdravilo Rinvoq, bo zdravstvenim delavcem zagotovilo informacije o tveganjih okužbe, škodljivosti za nerojenega otroka, če se zdravilo Rinvoq jemlje med nosečnostjo, in težavah, ki vplivajo na srce in krvni obtok.
English: The company will also supply a patient alert card describing warning signs of Rinvoq's serious side effects and how to get help, and a reminder not to use it during pregnancy.
Slovenian: Pripravilo bo tudi opozorilno kartico za bolnike, na kateri bodo opisani opozorilni znaki resnih neželenih učinkov zdravila Rinvoq in navodila, kako naj bolniki poiščejo pomoč, ter opozorilo, da se zdravilo ne sme uporabljati med nosečnostjo.
English: Patients treated with Rinvoq may have side effects that include infection, neutropenia (low count of a type of white blood cell), and blood tests that suggest liver or muscle damage and raised blood lipids.
Slovenian: Pri bolnikih, ki se zdravijo z zdravilom Rinvoq, se lahko pojavijo neželeni učinki, ki vključujejo okužbo, nevtropenijo (nizko število vrste belih krvnih celic), krvne preiskave pa kažejo na okvaro jeter ali poškodbe mišic in povečano raven krvnih lipidov.
English: It can be used on its own or with methotrexate, another medicine for rheumatoid arthritis.
Slovenian: Zdravilo se lahko uporablja samostojno ali v kombinaciji z metotreksatom, tj. drugim zdravilom za zdravljenje revmatoidnega artritisa.
English: Rinvoq is used for moderate or severe rheumatoid arthritis that cannot be controlled well enough with disease-modifying anti-rheumatic medicines or if the patient cannot take these medicines.
Slovenian: Zdravilo Rinvoq se uporablja pri zmernem ali hudem revmatoidnem artritisu, ki ga ni mogoče dovolj dobro nadzorovati z imunomodulirajočimi antirevmatiki, ali kadar bolnik teh zdravil ne more jemati.
English: The fifth study involved patients for whom a biological disease-modifying anti-rheumatic medicine was either not suitable or did not work well enough.
Slovenian: V peto študijo so bili vključeni bolniki, za katere biološki imunomodulirajoči antirevmatik ni bil primeren ali pa ni bil dovolj učinkovit.
English: Rinvoq is a medicine for treating adults with rheumatoid arthritis, a disease that causes inflammation of the joints.
Slovenian: Rinvoq je zdravilo za zdravljenje odraslih z revmatoidnim artritisom, tj. boleznijo, ki povzroča vnetje sklepov.
English: What are the risks associated with Rinvoq?
Slovenian: Kakšna tveganja so povezana z zdravilom Rinvoq?
English: What is Rinvoq and what is it used for?
Slovenian: Kaj je zdravilo Rinvoq in za kaj se uporablja?
English: Upadacitinib, the active substance in Rinvoq, is an immunosuppressant.
Slovenian: Upadacitinib, učinkovina v zdravilu Rinvoq, je imunosupresiv.
English: The first study was in patients who had not previously been treated with methotrexate.
Slovenian: Prva študija je vključevala bolnike, ki predhodno niso bili zdravljeni z metotreksatom.
English: Of the patients who also received Rinvoq, 43% had low disease activity compared with 14% of patients receiving placebo.
Slovenian: Med bolniki, ki so prejemali tudi zdravilo Rinvoq, jih je 43 % imelo nizko aktivnost bolezni v primerjavi s 14 % bolnikov, ki so prejemali placebo.
English: Rinvoq was effective at controlling moderate to severe rheumatoid arthritis in patients whose disease had not improved enough with other disease-modifying anti-rheumatic medicines.
Slovenian: Zdravilo Rinvoq je bilo učinkovito pri nadzoru zmernega do hudega revmatoidnega artritisa pri bolnikih, pri katerih zdravljenje z drugimi imunomodulirajočimi antirevmatiki ni zagotovilo zadostnega izboljšanja.
English: It found that 45% of the patients treated with Rinvoq on its own had low disease activity after 14 weeks compared with 19% of patients continuing their methotrexate treatment.
Slovenian: Ugotovljeno je bilo, da je imelo 45 % bolnikov, zdravljenih samo z zdravilom Rinvoq, po 14 tednih nizko aktivnost bolezni v primerjavi z 19 % bolnikov, ki so se še naprej zdravili z metotreksatom.
English: How is Rinvoq used?
Slovenian: Kako se zdravilo Rinvoq uporablja?
English: It found that 45% of patients treated with methotrexate plus Rinvoq had low disease activity after 12 weeks compared with 29% of patients treated with methotrexate plus adalimumab (a biological diseasemodifying anti-rheumatic medicine) and 14% of patients receiving methotrexate plus placebo.
Slovenian: Ugotovljeno je bilo, da je imelo 45 % bolnikov, zdravljenih z metotreksatom in zdravilom Rinvoq, po 12 tednih nizko aktivnost bolezni v primerjavi z 29 % bolnikov, zdravljenih z metotreksatom in adalimumabom (biološkim imunomodulirajočim antirevmatikom), in 14 % bolnikov, ki so prejemali metotreksat in placebo.
English: For the full list of side effects of Rinvoq, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Rinvoq, glejte navodilo za uporabo.
English: Rinvoq can only be obtained with a prescription.
Slovenian: Predpisovanje in izdaja zdravila Rinvoq je le na recept.
English: The second study was in patients whose disease was not well controlled with disease-modifying antirheumatic medicines.
Slovenian: Druga študija je zajela bolnike, pri katerih bolezen ni bila dobro nadzorovana z imunomodulirajočimi antirevmatiki.
English: The fourth study was also in patients whose disease was not controlled well enough with methotrexate.
Slovenian: Tudi četrta študija je vključevala bolnike, pri katerih bolezen ni bila dobro nadzorovana z metotreksatom.
English: How does Rinvoq work?
Slovenian: Kako zdravilo Rinvoq deluje?
English: The third study was in patients whose disease was not controlled well with methotrexate.
Slovenian: Tretja študija je vključevala bolnike, pri katerih bolezen ni bila dobro nadzorovana z metotreksatom.
English: It found that of patients treated with Rinvoq, 48% had low disease activity after 12 weeks compared with 17% of patients receiving placebo (a dummy treatment).
Slovenian: Ugotovljeno je bilo, da je imelo 48 % bolnikov, zdravljenih z zdravilom Rinvoq, po 12 tednih nizko aktivnost bolezni v primerjavi s 17 % bolnikov, ki so prejemali placebo (zdravilo brez učinkovine).
English: It found that after 24 weeks, 48% of patients were in remission (clear of symptoms) after treatment with Rinvoq compared with 19% of patients receiving methotrexate.
Slovenian: Ugotovljeno je bilo, da je po 24 tednih zdravljenja z zdravilom Rinvoq remisijo (stanje brez simptomov) doseglo 48 % bolnikov, v primerjavi z 19 % bolnikov, ki so prejemali metotreksat.
English: Rinvoq contains the active substance upadacitinib.
Slovenian: Zdravilo Rinvoq vsebuje učinkovino upadacitinib.
English: Unopened: 3 years.
Slovenian: Neodprto: 3 leti.
English: No action required except continued monitoring.
Slovenian: Ukrepi niso potrebi, razen nadaljevanja spremljanja.
English: Date of first authorization: 11 October 2000 Date of latest renewal: 27 September 2010
Slovenian: Datum pridobitve podaljšanja dovoljenja: 11. oktober 2000 Datum zadnjega podaljšanja dovoljenja: 27.september 2010
English: • Women planning a pregnancy.
Slovenian: • Ženske, ki načrtujejo nosečnost.
English: 0 = No reaction
Slovenian: 0 = Brez reakcije
English: There are no specific recommendations for use in elderly men (above 65 years of age).
Slovenian: Ni določenih priporočil za uporabo pri starejših moških (nad starostjo 65 let).
English: Infection, including bacterial infection
Slovenian: okužba, vključno z bakterijsko okužbo
English: Apply the next dose at the usual time.
Slovenian: Naslednji odmerek nanesite ob običajnem času.
English: Grade 0, 1 or 2
Slovenian: Stopnja 0, 1 ali 2
English: It is important that you consult your doctor, who will tell you what to do.
Slovenian: Pomembno je, da se obrnete na svojega zdravnika, ki vam bo razložil, kaj je potrebno storiti.
English: • Do not be discouraged if you do not see immediate improvement.
Slovenian: • Ne odnehajte, če ne opazite takojšnjega izboljšanja.
English: • Do not stop treatment at the first sign of improvement.
Slovenian: • Ne prenehajte z zdravljenjem po prvih znakih izboljšanja.
English: In-use: Any remaining tube should be discarded 90 days after first opening.
Slovenian: Med uporabo: Preostanek vsebine v tubi je treba 90 dni po prvem odprtju zavreči.
English: Safety and effectiveness in women have not been established because of the paucity of clinical data.
Slovenian: Varnost in učinkovitost pri ženskah nista bili ugotovljeni zaradi majhnega obsega kliničnih podatkov.
English: Allergic reaction
Slovenian: Alergijske reakcije
English: Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Slovenian: Obvestite zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katero koli drugo zdravilo, tudi če ste jih dobili brez recepta.
English: No specific studies on fertility have been conducted in men or women.
Slovenian: Specifičnih študij plodnosti pri moških ali ženskah niso izvajali.
English: The medicinal product was not genotoxic.
Slovenian: Zdravilo se ni izkazalo kot genotoksično.
English: Study 2 (BD)
Slovenian: Študija 2 (BD)
English: In Study 2a (N = 99), the overall response rate increased to 56.1%.
Slovenian: V študiji 2a (N = 99) se je skupna stopnja odziva povečala na 56,1 %.
English: The frequency of adverse events are classified as very common (≥1/10), common (≥1/100 to <1/10), and uncommon (≥1/1,000 to <1/100).
Slovenian: Pogostnost pojavljanja neželenih učinkov je uvrščena kot zelo pogosta (≥1/10), pogosta (≥1/100 do <1/10) in občasna (≥1/1.000 do <1/100) .
English: However there could be individual factors (e.g. damaged skin barrier, excessive use) that contribute to an increased systemic exposure.
Slovenian: Vendar pa lahko posamezni dejavniki (npr. poškodovana kožna pregrada, prekomerna uporaba) prispevajo k povečani sistemski izpostavljenosti.
English: System Organ Class (MedDRA terminology)
Slovenian: Organski sistem (terminologija po MedDRA)
English: Stable Disease %
Slovenian: Stabilna bolezen %
English: No case of overdose has been reported.
Slovenian: O primerih prevelikega odmerjanja niso poročali.
English: TREATMENT ADJUSTMENTS
Slovenian: PRILAGODITEV ZDRAVLJENJA
English: 4 = Very severe
Slovenian: 4 = Zelo hudo
English: At Least One At Least Four
Slovenian: Najmanj štiri
English: Definite pink to red coloration
Slovenian: Razločna rožnata do rdeča barva
English: - Panretin contains alcohol.
Slovenian: - Zdravilo Panretin vsebuje alkohol.
English: Pharmacotherapeutic group: other antineoplastic agents, ATC code: LO1XX22
Slovenian: Farmakoterapevtska skupina: drugi antineoplastiki, Oznaka ATC: LO1XX22
English: In study 1, of 110 responding patients, 36 (33%) relapsed, while all but four still being on active treatment.
Slovenian: V študiji 1 je od 110 bolnikov, ki so se odzvali, 36 (33 %) ponovno zbolelo, medtem ko so z izjemo štirih bili še vsi na aktivnem zdravljenju.
English: Therefore, there is a low potential for interactions with systemic medicinal products.
Slovenian: Zato obstaja le majhna možnost medsebojnega delovanja s sistemskimi snovmi.
English: Study 2 was followed by an open label study (Study 2a), which included only patients electing to continue from Study 2.
Slovenian: Za študijo 2 je sledila odprta faza (študija 2a), v kateri so sodelovali le bolniki, ki so bili izbrani za nadaljevanje študije 2.
English: Clinical Complete Response (CCR) %
Slovenian: Celotni klinični odziv (CCR) %
English: Only two serious adverse reactions were reported (sepsis and cellulitis in the same patient).
Slovenian: Poročali so le o dveh hudih neželenih učinkih (sepsa in celulit pri istem bolniku).
English: DEFINING CLINICAL SIGNS
Slovenian: OPREDELITEV KLINIČNIH ZNAKOV
English: • Treatment of KS lesions in close proximity to other skin disorders.
Slovenian: • Zdravljenje KS lezij, ki se pojavijo v neposredni bližini drugih bolezni kože.
English: The incidence of severe skin rash was independent of the duration of treatment (10% in both cases).
Slovenian: Pojav hudih izpuščajev ni bil povezan s trajanjem zdravljenja (10 % v obeh primerih).
English: A subset of these patients were followed during treatment of up to 64 lesions (range 4-64, median 11.5 lesions) for up to 44 weeks (range 2-44, median 15 weeks).
Slovenian: Del teh bolnikov so spremljali za zdravljenje do 64 lezij (razpon 4-64, povprečje 11,5 lezij) in do 44 tednov (razpon 2-44, povprečje 15 tednov).
English: However, an increased rate of fused sternebrae was observed.
Slovenian: Vendar pa so opazili povečano pogostnost fuzije prsnice (sternebrae).